---
title: "Why Novo Nordisk Stock Crumbled Again Today"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/251070516.md"
description: "Novo Nordisk's stock fell nearly 6% after HSBC analyst Rajesh Kumar downgraded it from buy to hold, lowering the price target from 680 krone to 360 krone. Kumar expressed concerns over competition from compounded weight-loss drugs, which continue to be sold illegally despite FDA bans. He believes current estimates for GLP-1 drug sales may be overestimated. However, some analysts argue that the popularity of Wegovy and Ozempic could still drive growth, depending on enforcement of the compounding ban."
datetime: "2025-07-31T22:07:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251070516.md)
  - [en](https://longbridge.com/en/news/251070516.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251070516.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/251070516.md) | [繁體中文](https://longbridge.com/zh-HK/news/251070516.md)


# Why Novo Nordisk Stock Crumbled Again Today

The hits just kept coming for beleaguered Ozempic and Wegovy maker **Novo Nordisk** (NVO -6.05%) on Thursday. The company, which has been slammed with investor sell-offs since cutting its guidance on Tuesday, fell by almost 6% as yet another analyst weighed in with a bearish take on its prospects. The **S&P 500** index, meanwhile, traded down only slightly.

## A downgrade to hold

That pundit was **HSBC**'s Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning.

Image source: Getty Images.

Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) per share from the preceding 680 krone ($104.81).

According to reports, Kumar particularly expressed concern about compounded weight-loss drugs, a form of competition that has affected Novo Nordisk's otherwise lively Ozempic and Wegovy sales. The analyst wrote that although the U.S. Food and Drug Administration (FDA) has banned compounding, rivals continue to sell such drugs illegally.

Kumar does not believe this situation will change much in the near future, so he believes current estimates for total GLP-1 drug sales might be overestimated.

## Reasons to be cheerful

The HSBC pundit certainly raises valid concerns and questions, although the ultimate effect of the compounding ban on Novo Nordisk will depend on how effectively it's enforced; perhaps, in contrast to Kumar's view, the offending parties will be caught and punished.

I wouldn't be as down on the Danish company as the analyst. That hot competition only proves how popular Wegovy and its ilk are at the moment, and in a vast country like the U.S. that has a clear problem with obesity, that should continue to motor its fundamentals higher.

### 相关股票

- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-CN/quote/NVO.US.md)

## 相关资讯与研究

- [As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?](https://longbridge.com/zh-CN/news/270794581.md)
- [Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch](https://longbridge.com/zh-CN/news/272836281.md)
- [PayPay Stock Surges Amid Post-IPO Fluctuations](https://longbridge.com/zh-CN/news/279072293.md)
- [Dr. Reddy’s Flags Phase III Setback as Immutep Halts Key Lung Cancer Trial](https://longbridge.com/zh-CN/news/279076056.md)
- [Signing Day Sports Finalizes BlockchAIn Merger Share Terms](https://longbridge.com/zh-CN/news/279094761.md)